Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

697
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
697
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

714
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
714
Drug Regulation01:25

Drug Regulation

1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Drug-Drug Interaction Studies Inform Drug Labeling: A Survey of US Food and Drug Administration-Approved New Molecular Entities from 1998 to 2022.

Clinical pharmacology and therapeutics·2026
Same author

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Advancing IBD Management: A Literature Review on the Role of Non-Invasive Blood-Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment.

Clinical and translational science·2026
Same author

The pH factor: unraveling drug-drug interactions in protein kinase inhibitors through the regulatory lens.

Translational and clinical pharmacology·2026
Same author

Beyond Impossibility: Reimagining Clinical Evidence for Children with Ultra-Rare Diseases.

Journal of clinical pharmacology·2026
Same author

Utilization of Model-Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for Treatment of Sickle Cell Disease.

CPT: pharmacometrics & systems pharmacology·2026

Related Experiment Video

Updated: Jun 21, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.3K

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development.

Amitava Mitra1, Nessy Tania2, Mariam A Ahmed3

  • 1Clinical Pharmacology, Kura Oncology Inc., Boston, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|July 11, 2024
PubMed
Summary

Model-informed approaches enhance drug development by integrating data for a stronger risk-benefit profile, especially transforming rare diseases drug development with limited patient populations.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.8K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Related Experiment Videos

Last Updated: Jun 21, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.3K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.8K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Area of Science:

  • Pharmacometrics and Quantitative Pharmacology
  • Drug Development and Regulatory Science
  • Rare Diseases Research

Background:

  • Model-informed approaches offer a quantitative framework for integrating diverse data in drug development.
  • Maximizing data utilization enhances risk-benefit assessment and reduces uncertainty.
  • These methods are crucial for rare diseases where traditional trials are challenging.

Purpose of the Study:

  • To discuss the application of novel quantitative approaches in drug development.
  • To showcase case studies of these modeling approaches in rare diseases.
  • To share perspectives on the future of these tools in rare diseases drug development.

Main Methods:

  • Quantitative systems pharmacology
  • Disease progression modeling
  • Artificial intelligence and machine learning
  • Real-world data modeling (model-based meta-analysis)
  • External controls and patient-reported outcomes
  • Clinical trial simulations

Main Results:

  • Model-informed approaches provide a totality of evidence for robust risk-benefit characterization.
  • These methods can support regulatory approval without additional clinical data.
  • Case studies demonstrate successful applications in rare diseases drug development.

Conclusions:

  • Model-informed approaches are transformative for rare diseases drug development.
  • These quantitative tools optimize trials, reduce uncertainty, and support regulatory decisions.
  • Future opportunities exist for incorporating these methods into rational drug product development.